Rigel Pharmaceuticals
Clinical trials sponsored by Rigel Pharmaceuticals, explained in plain language.
-
New drug R289 offers hope for blood cancer patients who failed other therapies
Disease control Recruiting nowThis study tests a new drug called R289 in adults with a type of blood cancer called lower-risk myelodysplastic syndromes (MDS) that has not improved with standard treatments. The main goal is to check if R289 is safe and tolerable, and to see if it can reduce or eliminate the ne…
Phase: PHASE1, PHASE2 • Sponsor: Rigel Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 06:20 UTC
-
New study reveals how cancer drug affects other medications
Knowledge-focused Recruiting nowThis study looks at how olutasidenib, a drug for certain cancers with an IDH1 mutation, changes the way the body processes other medications. Researchers will give participants a mix of test drugs before and during olutasidenib treatment to measure differences in drug levels. The…
Phase: PHASE4 • Sponsor: Rigel Pharmaceuticals • Aim: Knowledge-focused
Last updated May 17, 2026 06:17 UTC